UY25878A1 - Análogos nucleósidos antivirales - Google Patents

Análogos nucleósidos antivirales

Info

Publication number
UY25878A1
UY25878A1 UY25878A UY25878A UY25878A1 UY 25878 A1 UY25878 A1 UY 25878A1 UY 25878 A UY25878 A UY 25878A UY 25878 A UY25878 A UY 25878A UY 25878 A1 UY25878 A1 UY 25878A1
Authority
UY
Uruguay
Prior art keywords
alkynyl
alkenyl
alkyl
dioxolane
hydroxymethyl
Prior art date
Application number
UY25878A
Other languages
English (en)
Inventor
Nghe Nguyen-Ba
Original Assignee
Iaf Biochem Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iaf Biochem Int filed Critical Iaf Biochem Int
Publication of UY25878A1 publication Critical patent/UY25878A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cisnucleósido de fórmula (I) represaentada en la figura 1, presentado en su forma de enantiómero (-), enantiómero (+), y mezclas de los mismos, incluyendo mezclas racémicas, como también sus sales farmacéuticamente aceptables, donde: n es 1 o 2; R3 es H o alquilo C1-6, alquenilo C2-6, alquinilo C2-6; r4 se elige entre H, COOH, CONH2, OH, SH, NH2, NO2, alquilo, alquenilo, alquinilo, halógeno, CORa (donde Ra es un alquilo, alquenilo o alquinilo) y COORb (donde Rb es un alquilo, alquenilo o alquinilo); X es H, monofosfato, difosfato, trifosfato, carbonilo sustituido con alquilo, alquenilo, alquinilo, arilo, o el grupo representado en la figura 2, donde Rc es H, alquilo, alquenilo, alquinilo o un grupo protector OH. Ejemplos de compuestos de fórmula general (I): Cis-2-hidroximetil-4-(2'-amino-6'-ciclopropilaminopurin-9'-il)-1,3-dioxolano; Cis-2-hidroximetil-4-(2'-amino-6'-ciclobutilaminopurin-9'-il)-1,3-dioxolano; (-)-(2r,4r)-2- hidroximetil-4-(2'-amino-6'-ciclopropilaminopurin-9'-il)-1,3-dioxolano libre; entre otros. Estos compuestos son útiles como agentes antivirales, más especifiamente para el tratamiento de infecciones de VIH y VHB. También se incluye una combinación de los compuestos descritos o sales farmacéuticamente aceptables de los mismos que comprenden al menos un agente terapéutico adicional elegido entre análogos nucleosídicos, inhibidores no nucleósidfos de la transcriptasa revertida o inhibidores de proteasa.
UY25878A 1998-12-23 1999-12-23 Análogos nucleósidos antivirales UY25878A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11379798P 1998-12-23 1998-12-23
US09/468,813 US6358963B1 (en) 1998-12-23 1999-12-22 Antiviral nucleoside analogues

Publications (1)

Publication Number Publication Date
UY25878A1 true UY25878A1 (es) 2001-08-27

Family

ID=22351590

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25878A UY25878A1 (es) 1998-12-23 1999-12-23 Análogos nucleósidos antivirales

Country Status (27)

Country Link
US (3) US6358963B1 (es)
EP (1) EP1140937B1 (es)
JP (1) JP2002533470A (es)
KR (1) KR100653485B1 (es)
CN (1) CN1117751C (es)
AP (1) AP2001002207A0 (es)
AT (1) ATE254126T1 (es)
AU (1) AU760875B2 (es)
BR (1) BR9916849A (es)
CA (1) CA2355712C (es)
CZ (1) CZ20012352A3 (es)
DE (1) DE69912842T2 (es)
DK (1) DK1140937T3 (es)
EA (1) EA004767B1 (es)
ES (1) ES2209532T3 (es)
HU (1) HUP0104827A3 (es)
ID (1) ID30477A (es)
IL (1) IL143867A0 (es)
MX (1) MXPA01006425A (es)
NO (1) NO20013163L (es)
NZ (1) NZ513094A (es)
OA (1) OA11741A (es)
PT (1) PT1140937E (es)
TR (1) TR200102501T2 (es)
UY (1) UY25878A1 (es)
WO (1) WO2000039143A2 (es)
ZA (1) ZA200105702B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA11741A (en) * 1998-12-23 2005-05-13 Iaf Biochem Int Antiviral nucleoside analogues.
ATE360016T1 (de) * 2000-02-11 2007-05-15 Shire Biochem Inc Ein stereoselektives verfahren zur herstellung von nukleosidanalogen
AU2003261114A1 (en) * 2002-07-03 2004-02-09 Triangle Pharmaceuticals, Inc. Combination therapy with 1,3-dioxolanes and inosine monophosphate dehydrogenase inhibitors
ES2360096T3 (es) 2002-08-06 2011-05-31 Pharmasset, Inc. Procedimientos de preparación de nucleosidos de 1,3-dioxolano.
US7706405B2 (en) * 2002-09-12 2010-04-27 Interdigital Technology Corporation System for efficient recovery of Node-B buffered data following MAC layer reset
JP4501135B2 (ja) * 2002-11-18 2010-07-14 シェア カナダ インコーポレーテッド ジオキソランヌクレオシド類似体の立体選択的製造方法
DE10335061B4 (de) * 2003-07-31 2005-11-17 Wacker-Chemie Gmbh Verfahren zur Herstellung von OH-geschützten [4-(2,6-damino-9H-purin-9-yl)-1,3-dioxolan-2-yl]methanol-Derivaten
US7785839B2 (en) 2004-02-03 2010-08-31 Emory University Methods to manufacture 1,3-dioxolane nucleosides
US7322412B2 (en) * 2004-08-30 2008-01-29 Halliburton Energy Services, Inc. Casing shoes and methods of reverse-circulation cementing of casing
ATE516249T1 (de) * 2008-03-20 2011-07-15 Befesa Salzschlacke Gmbh Hochtonerdehaltiger rohstoff und verfahren zur herstellung
WO2012048455A1 (zh) * 2010-10-12 2012-04-19 武汉大学 一种抗病毒透皮吸收贴片及其制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000137A (en) 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
US4041037A (en) 1975-06-10 1977-08-09 American Home Products Corporation Antitumor derivatives of periodate-oxidized cytidine
JPS5668674A (en) 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
JPS5738774A (en) 1980-08-19 1982-03-03 Chugai Pharmaceut Co Ltd Uracil derivative and its preparation
US4479942A (en) 1981-08-10 1984-10-30 Fujisawa Pharmaceutical Co., Ltd. Tetrahydrofurnancarboxylic acid derivatives, processes for preparation thereof and pharmaceutical compositions thereof
IL86007A0 (en) * 1987-04-09 1988-09-30 Wellcome Found 6-substituted purine nucleosides,their preparation and pharmaceutical compositions containing them
HU198933B (en) 1987-11-02 1989-12-28 Chinoin Gyogyszer Es Vegyeszet Process for producing new xanthine derivatives and pharmaceutical compositions comprising same as active ingredient
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5041449A (en) 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5270315A (en) 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US4987224A (en) 1988-08-02 1991-01-22 University Of Georgia Research Foundation, Inc. Method of preparation of 2',3'-dideoxynucleosides
AU3154993A (en) 1989-02-08 1994-07-19 Biochem Pharma Inc. Process for preparing substituted 1,3-oxathiolanes with antiviral properties
PT95516A (pt) * 1989-10-06 1991-08-14 Wellcome Found Processo para a preparacao de derivados de 2',3'-didesoxi nucleosidos 6-substituidos
US5700937A (en) 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5276151A (en) 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
WO1992008717A1 (en) 1990-11-13 1992-05-29 Biochem Pharma Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
US5444063A (en) 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
WO1992010496A1 (en) 1990-12-05 1992-06-25 University Of Georgia Research Foundation, Inc. ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES
US5925643A (en) 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5179104A (en) 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
IL100965A (en) 1991-02-22 1999-12-31 Univ Emory 2 - Hydroxymethyl - 5 -) 5 - Fluorocytocin - 1 - Eyal (- 1, 3 - Oxathiolane, its resolution and pharmaceuticals containing it
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9109506D0 (en) 1991-05-02 1991-06-26 Wellcome Found Therapeutic nucleosides
GB9110874D0 (en) 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923640B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9200150D0 (en) 1992-01-06 1992-02-26 Wellcome Found Therapeutic nucleosides
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
GB9525606D0 (en) * 1995-12-14 1996-02-14 Iaf Biochem Int Method and compositions for the synthesis of dioxolane nucleosides with › - configuration
US5792773A (en) 1996-11-15 1998-08-11 Yale University L-β-dioxolane uridine analog administration for treating Epstein-Barr virus infection
OA11741A (en) * 1998-12-23 2005-05-13 Iaf Biochem Int Antiviral nucleoside analogues.

Also Published As

Publication number Publication date
ID30477A (id) 2001-12-13
CN1334814A (zh) 2002-02-06
CA2355712C (en) 2009-03-17
DE69912842D1 (de) 2003-12-18
US6358963B1 (en) 2002-03-19
AP2001002207A0 (en) 2001-09-30
IL143867A0 (en) 2002-04-21
CZ20012352A3 (cs) 2001-10-17
CN1117751C (zh) 2003-08-13
EA200100711A1 (ru) 2001-12-24
US20040058893A1 (en) 2004-03-25
HUP0104827A3 (en) 2002-08-28
KR20020013485A (ko) 2002-02-20
AU1765700A (en) 2000-07-31
DK1140937T3 (da) 2004-03-22
DE69912842T2 (de) 2004-05-13
NO20013163L (no) 2001-08-20
NO20013163D0 (no) 2001-06-22
ES2209532T3 (es) 2004-06-16
WO2000039143A2 (en) 2000-07-06
MXPA01006425A (es) 2002-06-04
BR9916849A (pt) 2001-10-30
PT1140937E (pt) 2004-04-30
OA11741A (en) 2005-05-13
ZA200105702B (en) 2002-10-11
AU760875B2 (en) 2003-05-22
US6545001B2 (en) 2003-04-08
JP2002533470A (ja) 2002-10-08
KR100653485B1 (ko) 2006-12-04
US20010049372A1 (en) 2001-12-06
ATE254126T1 (de) 2003-11-15
TR200102501T2 (tr) 2002-01-21
NZ513094A (en) 2004-05-28
EP1140937A2 (en) 2001-10-10
CA2355712A1 (en) 2000-07-06
EP1140937B1 (en) 2003-11-12
EA004767B1 (ru) 2004-08-26
WO2000039143A3 (en) 2000-11-02
HUP0104827A2 (en) 2002-06-29

Similar Documents

Publication Publication Date Title
NO2022019I1 (no) Eribulin eller et farmasøytisk akseptabelt salt derav - forlenget SPC
UY25878A1 (es) Análogos nucleósidos antivirales
PL409123A1 (pl) Związki, ich zastosowanie i kompozycje do leczenia wirusowego zapalenia wątroby typu C
GT199900166A (es) Compuesto quìmico adecuado para usar como agente antiviral.-
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
ES2131116T3 (es) Analogos de nucleotidos enantiomericos antirretrovirales.
AR029766A1 (es) Compuesto inhibidor de quinasa y uso del mismo para preparar una composicion farmaceutica
CR6951A (es) Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgesicos.
HUP0001309A2 (hu) 1-Fenil-4-benzil-piperazinok és a vegyületeket tartalmazó gyógyászati készítmények
CO4810375A1 (es) Derivados de 9-amino-3-ceto eritromicina
HUP0302980A2 (hu) Lipofil és ionizálható molekularészeket tartalmazó protein junkinázgátló hatású szulfonamid-származékok és ezeket tartalmazó gyógyszerkészítmények
BR9810947A (pt) "derivativos de bis-indol tendo atividade antimestastática, processo para o seu preparo e composições farmacêuticas que os contêm"
HUP0200312A2 (hu) Szubsztituált 2-fenil-benzimidazolok, ezeket tartalmazó gyógyszerkészítmények, előállításuk és alkalmazásuk
UY26872A1 (es) Derivados de la 4- fenil piridina
CL2004000174A1 (es) Compuestos derivados de malonamida n,n'-disustituidos; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de la enfermedad de alzheimer.
PA8580301A1 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
UY26276A1 (es) 1,2,4,5- tetrahidro-benzo (d) azepinas ley 17164
PA8536001A1 (es) Derivados de quinazolona como antagonistas de receptores adrenérgicos alfa-1a/b
DK1224940T4 (da) Flydende formuleringer af interferon-beta
DK1165096T3 (da) Anvendelse af cytidinderivater til behandling af leukæmi
AR009413A1 (es) Un compuesto, el cual es un derivado de distamicina benzoheterociclico, su utilizacion, un procedimiento para producirlo y una composicionfarmaceutica que lo comprende
SE9703375D0 (sv) A new combination
AR028624A1 (es) Heterociclilalquilaminas como antagonistas de receptores muscarinicos
AR029373A1 (es) Metodo para el tratamiento de migranas, utilizando compuestos antagonistas selectivos de los receptores iglur5, uso de dichos compuestos antagonistas selectivos en la manufactura de medicamentos para el tratamiento de migranas y dichos compuestos antagonistas
UY27786A1 (es) Derivados de isoquinolina.

Legal Events

Date Code Title Description
ABAN Application deemed to be withdrawn (no publication fee paid)

Effective date: 20090820